U.S. Stock Movement | Positive Phase 1 Trial Data for MRT-8102 Sends Monte Rosa Therapeutics (GLUE.US) Soaring Over 42% Pre-Market

Stock News01-07

On Wednesday, shares of Monte Rosa Therapeutics (GLUE.US) surged more than 42% in pre-market trading to $22.76. The catalyst for the move was positive interim data from the ongoing Phase 1 trial of MRT-8102, showing a reduction in C-reactive protein levels associated with cardiovascular and cardiometabolic diseases. In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102—an investigational NEK7-targeting molecular glue degrader for treating NLRP3/IL-1/IL-6-driven inflammatory diseases—demonstrated rapid and sustained systemic reduction of inflammation. After four weeks of treatment with MRT-8102, C-reactive protein (CRP) levels decreased by 85%, and 94% of study participants achieved a CRP value below 2 mg/L, a threshold linked to a lower risk of cardiovascular disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106952022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106952022","market":"other","top_or_hot":-1,"title":"U.S. Stock Movement | Positive Phase 1 Trial Data for MRT-8102 Sends Monte Rosa Therapeutics (GLUE.US) Soaring Over 42% Pre-Market","media":"Stock News","content":"<p>On Wednesday, shares of Monte Rosa Therapeutics (GLUE.US) surged more than 42% in pre-market trading to $22.76.\nThe catalyst for the move was positive interim data from the ongoing Phase 1 trial of MRT-8102, showing a reduction in C-reactive protein levels associated with cardiovascular and cardiometabolic diseases.\nIn subjects with elevated cardiovascular disease (CVD) risk, MRT-8102—an investigational NEK7-targeting molecular glue degrader for treating NLRP3/IL-1/IL-6-driven inflammatory diseases—demonstrated rapid and sustained systemic reduction of inflammation.\nAfter four weeks of treatment with MRT-8102, C-reactive protein (CRP) levels decreased by 85%, and 94% of study participants achieved a CRP value below 2 mg/L, a threshold linked to a lower risk of cardiovascular disease.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stock Movement | Positive Phase 1 Trial Data for MRT-8102 Sends Monte Rosa Therapeutics (GLUE.US) Soaring Over 42% Pre-Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stock Movement | Positive Phase 1 Trial Data for MRT-8102 Sends Monte Rosa Therapeutics (GLUE.US) Soaring Over 42% Pre-Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-07 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Wednesday, shares of Monte Rosa Therapeutics (GLUE.US) surged more than 42% in pre-market trading to $22.76.\nThe catalyst for the move was positive interim data from the ongoing Phase 1 trial of MRT-8102, showing a reduction in C-reactive protein levels associated with cardiovascular and cardiometabolic diseases.\nIn subjects with elevated cardiovascular disease (CVD) risk, MRT-8102—an investigational NEK7-targeting molecular glue degrader for treating NLRP3/IL-1/IL-6-driven inflammatory diseases—demonstrated rapid and sustained systemic reduction of inflammation.\nAfter four weeks of treatment with MRT-8102, C-reactive protein (CRP) levels decreased by 85%, and 94% of study participants achieved a CRP value below 2 mg/L, a threshold linked to a lower risk of cardiovascular disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLUE","symbol_name":"Monte Rosa Therapeutics","start_time":0,"source_url":"","article_id":"1106952022","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106952022","pubTimestamp":1767796220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On Wednesday, shares of Monte Rosa Therapeutics (GLUE.US) surged more than 42% in pre-market trading to $22.76. The catalyst for the move was positive interim data from the ongoing Phase 1 trial of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLUE":"Monte Rosa Therapeutics","BK4539":"次新股","BK4230":"旅客陆运","BK4139":"生物科技","MRT":"Marti Technologies Inc.","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"美股动向|MRT-8102积极的1期试验数据推动Monte Rosa Therapeutics(GLUE.US)盘前飙升超42%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"GLUE":1,"MRT":1},"content_text":"On Wednesday, shares of Monte Rosa Therapeutics (GLUE.US) surged more than 42% in pre-market trading to $22.76.\nThe catalyst for the move was positive interim data from the ongoing Phase 1 trial of MRT-8102, showing a reduction in C-reactive protein levels associated with cardiovascular and cardiometabolic diseases.\nIn subjects with elevated cardiovascular disease (CVD) risk, MRT-8102—an investigational NEK7-targeting molecular glue degrader for treating NLRP3/IL-1/IL-6-driven inflammatory diseases—demonstrated rapid and sustained systemic reduction of inflammation.\nAfter four weeks of treatment with MRT-8102, C-reactive protein (CRP) levels decreased by 85%, and 94% of study participants achieved a CRP value below 2 mg/L, a threshold linked to a lower risk of cardiovascular disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106952022","isCrawlerRequest":true}